Ftse Mib
34.532,29
0,75%
DAX
18.513,57
0,52%
S&P 500
5.291,34
0,15%
NASDAQ
16.857,05
0,17%
Bitcoin
70.848,01
0,32%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Corvus Pharmaceuticals Inc (CRVS) Corvus Pharmaceuticals Inc (CRVS) Notizie

CRVS

Corvus Pharmaceuticals (CRVS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CRVS
DataOraFonteTitoloSimboloCompagnia
30/05/202422:02GlobeNewswire Inc.Corvus Pharmaceuticals to Present at the Jefferies Global Health ConferenceNASDAQ:CRVSCorvus Pharmaceuticals Inc
07/05/202423:19Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CRVSCorvus Pharmaceuticals Inc
07/05/202423:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRVSCorvus Pharmaceuticals Inc
07/05/202423:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRVSCorvus Pharmaceuticals Inc
06/05/202422:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRVSCorvus Pharmaceuticals Inc
06/05/202422:01GlobeNewswire Inc.Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:CRVSCorvus Pharmaceuticals Inc
02/05/202422:02GlobeNewswire Inc.Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024NASDAQ:CRVSCorvus Pharmaceuticals Inc
02/05/202414:30GlobeNewswire Inc.Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct OfferingNASDAQ:CRVSCorvus Pharmaceuticals Inc
09/04/202422:01GlobeNewswire Inc.Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisNASDAQ:CRVSCorvus Pharmaceuticals Inc
19/03/202421:02GlobeNewswire Inc.Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CRVSCorvus Pharmaceuticals Inc
19/03/202412:27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:CRVSCorvus Pharmaceuticals Inc
13/03/202421:02GlobeNewswire Inc.Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024NASDAQ:CRVSCorvus Pharmaceuticals Inc
12/02/202414:30GlobeNewswire Inc.Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory DiseasesNASDAQ:CRVSCorvus Pharmaceuticals Inc
08/02/202422:27Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CRVSCorvus Pharmaceuticals Inc
08/02/202422:05GlobeNewswire Inc.Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell LymphomaNASDAQ:CRVSCorvus Pharmaceuticals Inc
06/02/202422:05GlobeNewswire Inc.Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business OfficerNASDAQ:CRVSCorvus Pharmaceuticals Inc
23/01/202423:00GlobeNewswire Inc.Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. MitchellNASDAQ:CRVSCorvus Pharmaceuticals Inc
09/12/202318:00GlobeNewswire Inc.Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma TrialNASDAQ:CRVSCorvus Pharmaceuticals Inc
07/11/202322:01GlobeNewswire Inc.Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:CRVSCorvus Pharmaceuticals Inc
02/11/202314:15GlobeNewswire Inc.Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & ExpositionNASDAQ:CRVSCorvus Pharmaceuticals Inc
02/11/202300:31GlobeNewswire Inc.Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune DiseasesNASDAQ:CRVSCorvus Pharmaceuticals Inc
31/10/202321:02GlobeNewswire Inc.Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023NASDAQ:CRVSCorvus Pharmaceuticals Inc
06/09/202322:05GlobeNewswire Inc.Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDANASDAQ:CRVSCorvus Pharmaceuticals Inc
08/08/202322:01GlobeNewswire Inc.Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:CRVSCorvus Pharmaceuticals Inc
01/08/202314:30GlobeNewswire Inc.Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023NASDAQ:CRVSCorvus Pharmaceuticals Inc
06/07/202318:59GlobeNewswire Inc.Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)NASDAQ:CRVSCorvus Pharmaceuticals Inc
29/06/202313:00GlobeNewswire Inc.Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International ConferenceNASDAQ:CRVSCorvus Pharmaceuticals Inc
21/06/202312:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CRVSCorvus Pharmaceuticals Inc
20/06/202323:02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CRVSCorvus Pharmaceuticals Inc
15/06/202313:00GlobeNewswire Inc.Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant LymphomaNASDAQ:CRVSCorvus Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CRVS

La tua Cronologia

BIT
UCG
Unicredit
BIT
ENEL
Enel
BIT
STLAM
Stellantis NV
BIT
ISP
Intesa Sanpaolo
BIT
ENI
Eni
BIT
STMMI
ST Microelectronics
BIT
TIT
Telecom Italia
BIT
SPM
Saipem
BIT
RACE
Ferrari NV
BIT
BPE
Bper Banca
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
SRG
Snam
BIT
PST
Poste Italiane S.p.a
BIT
PRY
Prysmian
BIT
BAMI
Banco BPM
BIT
LDO
Leonardo
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network